Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$87.10 USD

87.10
5,960,499

+0.90 (1.04%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $87.11 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Veeva Systems (VEEV) Offerings Adopted by Minaris Regenerative

by Zacks Equity Research

Veeva Systems' (VEEV) Vault Quality Suite applications are expected to aid the CDMO to modernize its operations and streamline its quality processes globally.

Medtronic (MDT) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Strong growth in the Cardiovascular, Medical Surgical, and Neuroscience portfolios, and in Diabetes markets drove Medtronic (MDT) Q4 revenues.

Masimo's (MASI) Platform Expansion to Boost Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) latest expansion to its HEOS platform will likely revolutionize health and wellness tracking by allowing connected care as consumers become tetherless and smartphone-less.

Boston Scientific (BSX) Gains From Acquisitions, New Launches

by Zacks Equity Research

Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.

Accuray (ARAY) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Accuray's (ARAY) solid product portfolio.

Veeva Systems' (VEEV) New Tie-Up to Improve Clinical Trials

by Zacks Equity Research

Veeva Systems' (VEEV) latest collaboration is expected to advance the patient experience in clinical trials.

Avantor's (AVTR) New Tie-Up to Improve Lab Inventory Management

by Zacks Equity Research

Avantor's (AVTR) latest partnership is expected to significantly optimize labs' inventory management and the overall workflow.

3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

3 Reasons to Hold Inspire Medical (INSP) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Inspire Medical (INSP) on the back of its product innovations.

BD's (BDX) Latest Product Launch to Boost Research Outcome

by Zacks Equity Research

BD's (BDX) latest cell sorting technology is expected to speed up the process of cell sorting and allow researchers to answer complex biological questions.

HCA Healthcare (HCA) Gains 29% in a Year: More Upside Left?

by Zacks Equity Research

HCA Healthcare (HCA) is well-poised for growth on the back of higher revenues, a diversified treatment network and sound operating cash flows.

Are Medical Stocks Lagging Boston Scientific (BSX) This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Aravive (ARAV) have performed compared to their sector so far this year.

Boston Scientific (BSX) Just Overtook the 20-Day Moving Average

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

Zacks Industry Outlook Highlights Stryker, Boston Scientific, Zimmer Biomet and Insulet

by Zacks Equity Research

Stryker, Boston Scientific, Zimmer Biomet and Insulet are part of the Zacks Industry Outlook article.

Indrajit Bandyopadhyay headshot

4 Medical Products Stocks to Capitalize on the Industry's Recovery

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

National Vision's (EYE) share price is likely to grow following the company's efforts to expand remote capabilities and investments in doctor recruiting and retention efforts.

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Tenet Healthcare's (THC) Q1 Earnings Beat, Shares Up 3.9%

by Zacks Equity Research

Tenet Healthcare's (THC) first-quarter 2023 results gain on increased patient volumes. Management presently expects adjusted EPS within $4.92-$6.09 in 2023, up from the prior view of $4.68-$5.85.

Boston Scientific (BSX) Q1 Earnings Beat, 2023 View Raised

by Zacks Equity Research

Reported and organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in the reported quarter.

Boston Scientific (BSX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Boston Scientific (BSX) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Boston Scientific (BSX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of 9.30% and 7.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Philips' (PHG) Q1 Earnings Jump Y/Y on Strong Top-Line Growth

by Zacks Equity Research

Philips' (PHG) first-quarter results benefit from robust performances by the Diagnosis & Treatment and the Connected Care businesses.

Urmimala Biswas headshot

MedTech Stocks' Q1 Earnings on Apr 25: BSX, TMO and More

by Urmimala Biswas

MedTech companies' results are likely to reflect a sequential decline. Let's see how BSX, TMO, EW and ALGN fare this time.

Here's Why You Should Buy Boston Scientific (BSX) Stock

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) owing to impressive growth in MedSurg market share.

What's in Store for Boston Scientific (BSX) in Q1 Earnings?

by Zacks Equity Research

Boston Scientific (BSX) is expected to have registered strong growth in EMEA within structural heart, including TAVR, WATCHMAN, and other interventional cardiology therapies in the first quarter.